{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:50:08Z","timestamp":1785880208826,"version":"3.56.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.berh.2026.102137","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:16:03Z","timestamp":1776021363000},"page":"102137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular and molecular mechanisms of systemic sclerosis: Translation to targeted therapies and clinical practice"],"prefix":"10.1016","volume":"40","author":[{"given":"Diane","family":"Documet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Ruser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-9890","authenticated-orcid":false,"given":"Monique","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvitha","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib1","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","article-title":"Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies","volume":"48","author":"Feghali-Bostwick","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2026.102137_bib2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S","article-title":"Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts","volume":"44","author":"Arnett","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102137_bib3","unstructured":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population - mayes - 2003 - arthritis & Rheumatism - wiley online library [Internet]. [cited 2026 Jan 11]. Available from: https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/art.11073?casa_token=4usH9T1L5xoAAAAA%3AjzW11OTyRgfHKtzvWiwKYRqBWioE-2LTgyTWfKjg4cqqmD_ItV0azLNJOGOUZ2HccekAc4G0-w926xk."},{"key":"10.1016\/j.berh.2026.102137_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2015.07.005","article-title":"Immunogenetics of systemic sclerosis: defining heritability, functional variants and shared-autoimmunity pathways","author":"Bossini-Castillo","year":"2015","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2010.02.001","article-title":"Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis","volume":"35","author":"Arora-Singh","year":"2010","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","article-title":"The HLA system: genetics, immunology, clinical testing, and clinical implications","volume":"48","author":"Choo","year":"2007","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.berh.2026.102137_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101981","article-title":"Insights into the genetic landscape of systemic sclerosis","volume":"38","author":"El-Halwagi","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/ard.2009.111906","article-title":"Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls","volume":"69","author":"Arnett","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102137_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110266","article-title":"Exploring the HLA complex in autoimmunity: from the risk haplotypes to the modulation of expression","volume":"265","author":"Sartoris","year":"2024","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.berh.2026.102137_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/art.42396","article-title":"Identification of mechanisms by which genetic susceptibility loci influence systemic sclerosis risk using functional genomics in primary T cells and monocytes","volume":"75","author":"Gonz\u00e1lez-Serna","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib11","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/s41598-020-58741-w","article-title":"A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease","volume":"10","author":"Gonz\u00e1lez-Serna","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2026.102137_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149666","article-title":"DDX6 is involved in the pathogenesis of inflammatory diseases via NF-\u03baB activation","volume":"703","author":"Naito","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib13","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"L\u00f3pez-Isac","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.berh.2026.102137_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-023-44541-z","article-title":"GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fc\u03b3 receptor region","volume":"15","author":"Ishikawa","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2026.102137_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101648","article-title":"Cellular and molecular diversity in scleroderma","author":"Hinchcliff","year":"2021","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2018.11.001","article-title":"Systemic sclerosis and exposure to heavy metals","volume":"18","author":"Marie","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102137_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102727","article-title":"Insights into the knowledge of complex diseases: environmental infectious\/toxic agents as potential etiopathogenetic factors of systemic sclerosis","volume":"124","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.berh.2026.102137_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051506","article-title":"Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis","volume":"7","author":"Barrag\u00e1n-Mart\u00ednez","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.berh.2026.102137_bib23","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the european scleroderma trial and research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2026.102137_bib24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41584-021-00683-2","article-title":"Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential","volume":"17","author":"Tsou","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.resinv.2025.07.008","article-title":"Molecular mechanisms and therapeutic developments of BMPR2 in pulmonary arterial hypertension","volume":"63","author":"Chen","year":"2025","journal-title":"Respir Investig"},{"issue":"10","key":"10.1016\/j.berh.2026.102137_bib26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/jcmm.12105","article-title":"Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma","volume":"17","author":"Wang","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"9","key":"10.1016\/j.berh.2026.102137_bib27","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1073\/pnas.1813006116","article-title":"Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma","volume":"116","author":"Tsou","year":"2019","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6075","article-title":"MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program","volume":"7","author":"Wang","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.berh.2026.102137_bib29","doi-asserted-by":"crossref","unstructured":"Dees C, P\u00f6tter S, Zhang Y, Bergmann C, Zhou X, Luber M, et al. TGF-\u03b2\u2013induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Investig. 130(5):2347\u20132363. doi:10.1172\/JCI122462 PubMed PMID: 31990678; PubMed Central PMCID: PMC7190914.].","DOI":"10.1172\/JCI122462"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib30","article-title":"Bromodomain and extraterminal (BET) protein inhibition restores redox balance and inhibits myofibroblast activation","volume":"2019","author":"Stock","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.berh.2026.102137_bib31","doi-asserted-by":"crossref","unstructured":"Vichaikul S, Gurrea-Rubio M, Amin MA, Campbell PL, Wu Q, Mattichak MN, et al. Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight. 7(9):e150871. doi:10.1172\/jci.insight.150871 PubMed PMID: 35349485; PubMed Central PMCID: PMC9090238.].","DOI":"10.1172\/jci.insight.150871"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdermsci.2017.04.013","article-title":"Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway","volume":"87","author":"Zhu","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"43","key":"10.1016\/j.berh.2026.102137_bib34","doi-asserted-by":"crossref","first-page":"69321","DOI":"10.18632\/oncotarget.12504","article-title":"SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis","volume":"7","author":"Akamata","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-016-1054-6","article-title":"miR-155 in the progression of lung fibrosis in systemic sclerosis","volume":"18","author":"Christmann","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102137_bib36","unstructured":"Targeting miR-155 to Treat Experimental Scleroderma | Sci Rep [Internet]. [cited 2025 Nov 10]. Available from: https:\/\/www.nature.com\/articles\/srep20314]."},{"key":"10.1016\/j.berh.2026.102137_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115282","article-title":"Further insight into systemic sclerosis from the vasculopathy perspective","volume":"166","author":"Ren","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.berh.2026.102137_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/BOR.0000000000001126","article-title":"Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications","volume":"37","author":"Massay","year":"2025","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102137_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2026.102137_bib40","unstructured":"Enrichment of scleroderma vascular disease\u2013associated autoantigens in endothelial lineage cells - McMahan - 2016 - arthritis & rheumatology - wiley online library [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39743."},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004290","article-title":"Immunoglobulins G from patients with systemic sclerosis modify the molecular signatures of endothelial cells","volume":"11","author":"Chepy","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2026.102137_bib42","article-title":"Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signatures","volume":"22","author":"Rouvi\u00e8re","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2026.102137_bib43","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.semarthrit.2015.10.013","article-title":"A review of the effects of statins in systemic sclerosis","volume":"45","author":"Ladak","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102137_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/11772719251318555","article-title":"Endothelin-1 as a candidate biomarker of systemic sclerosis: a GRADE-assessed systematic review and meta-analysis with meta-regression","volume":"20","author":"Mangoni","year":"2025","journal-title":"Biomark Insights"},{"issue":"24","key":"10.1016\/j.berh.2026.102137_bib45","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of Endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"issue":"12, Supplement","key":"10.1016\/j.berh.2026.102137_bib47","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jacc.2004.02.042","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension","volume":"43","author":"Channick","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib48","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keac426","article-title":"A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's","volume":"62","author":"Herrick","year":"2023","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib49","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/ijms23020927","article-title":"Antibodies against angiotensin II type 1 and endothelin 1 type A receptors in cardiovascular pathologies","volume":"23","author":"Civieri","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib50","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2026.102137_bib52","first-page":"375","article-title":"Pulmonary arterial hypertension incidence in patients with systemic sclerosis treated with bosentan for digital ulcers: evidence from the SPRING-SIR registry","volume":"52","author":"Cacciapaglia","year":"2025","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-022-02818-6","article-title":"Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial","volume":"24","author":"Stern","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib54","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102137_bib55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/annrheumdis-2019-eular.5755","article-title":"FRI0303 the effects of riociguat on RAYNAUD\u2019S phenomenon and digital ulcers in patients with diffuse systemic sclerosis: results from the phase IIB rise-SSC study","volume":"78","author":"Khanna","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/rheumatology\/keae049","article-title":"A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's","volume":"64","author":"Tornling","year":"2025","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib58","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCRESAHA.123.323299","article-title":"Characterization of vascular niche in systemic sclerosis by spatial proteomics","volume":"134","author":"Rius","year":"2024","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41467-023-44645-6","article-title":"Systems-based identification of the hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2026.102137_bib60","doi-asserted-by":"crossref","unstructured":"Wang X, Han X, Yu J, Hu F, Huang C, Chen C, et al. Chitinase 3-Like 1 promotes endothelial-to-mesenchymal transition in systemic sclerosis via mTORC1 signaling pathway. Arthritis Rheumatol. n\/a(n\/a). doi:10.1002\/art.43356].","DOI":"10.1002\/art.43356"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cei.13426","article-title":"Toll-like receptors in mediating pathogenesis in systemic sclerosis","volume":"201","author":"Frasca","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2026.102137_bib63","article-title":"Targeting tenascin-C-toll-like receptor 4 signalling with Adhiron-derived small molecules - a viable strategy for reducing fibrosis in systemic sclerosis","volume":"15","author":"Gaule","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.berh.2026.102137_bib64","doi-asserted-by":"crossref","unstructured":"Bhattacharyya S, Wang W, Qin W, Cheng K, Coulup S, Chavez S, et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight. 3(13):e98850. doi:10.1172\/jci.insight.98850 PubMed PMID: 29997297; PubMed Central PMCID: PMC6124522.].","DOI":"10.1172\/jci.insight.98850"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/art.42781","article-title":"Effect of Anti-S100A4 monoclonal antibody treatment on experimental skin fibrosis and systemic sclerosis\u2013specific transcriptional signatures in human skin","volume":"76","author":"Trinh-Minh","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102137_bib66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.imlet.2017.11.003","article-title":"Dendritic cells in systemic sclerosis: advances from human and mice studies","author":"Affandi","year":"2018","journal-title":"Immunol Lett"},{"issue":"78","key":"10.1016\/j.berh.2026.102137_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6691","article-title":"Epiregulin is a dendritic cell\u2013derived EGFR ligand that maintains skin and lung fibrosis","volume":"7","author":"Odell","year":"2022","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.42662","article-title":"Endothelial response to type I interferon contributes to vasculopathy and fibrosis and predicts disease progression of systemic sclerosis","volume":"76","author":"Yin","year":"2024","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13075-025-03632-6","article-title":"Transforming growth factor beta (TGF-\u03b2) induces type 1 interferon signalling in systemic sclerosis keratinocytes through the chloride intracellular channel 4 (CLIC4)","volume":"27","author":"Wasson","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.berh.2026.102137_bib70","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2665-9913(24)00403-X","article-title":"Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study","volume":"7","author":"Hinchcliff","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib71","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s41467-019-09683-z","article-title":"CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-\u03b1 production in systemic sclerosis","volume":"10","author":"Lande","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2026.102137_bib72","doi-asserted-by":"crossref","unstructured":"Mohammad Reza Beigi D, Porreca S, Muolo G, Ocone G, Landini N, Diana ME, et al. POS1098 ANTI-CXCL4 antibodies: novel potential biomarker of systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 2025 Jun 1;EULAR 2025: European Congress of Rheumatology84:1186\u20131187. doi:10.1016\/j.ard.2025.06.450].","DOI":"10.1016\/j.ard.2025.06.450"},{"issue":"3","key":"10.1016\/j.berh.2026.102137_bib73","first-page":"66","article-title":"Plasma CXCL4\u2013DNA\/RNA complexes and Anti-CXCL4 antibodies modulation in an SSc cohort under iloprost treatment","volume":"7","author":"Mennella","year":"2024","journal-title":"Y Rep"},{"key":"10.1016\/j.berh.2026.102137_bib74","unstructured":"Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases | N Engl J Med [Internet]. [cited 2026 Jan 10]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJM199610313351807."},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2026.102137_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103637","article-title":"The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: a systematic review","volume":"23","author":"Campitiello","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib77","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/art.41243","article-title":"Pro-fibrotic activation of human macrophages in systemic sclerosis","volume":"72","author":"Bhandari","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.berh.2026.102137_bib78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system","volume":"90","author":"Schellenburg","year":"2017","journal-title":"Mol Immunol"},{"issue":"11","key":"10.1016\/j.berh.2026.102137_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166433","article-title":"Alternatively activated (M2) macrophage phenotype is inducible by Endothelin-1 in cultured human macrophages","volume":"11","author":"Soldano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2026.102137_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115897","article-title":"Total glucosides of paeony alleviates scleroderma by inhibiting type I interferon responses","volume":"302","author":"Li","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.berh.2026.102137_bib81","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-021-02573-0","article-title":"An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod","volume":"23","author":"Hesselstrand","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","article-title":"Role of B cells in the pathogenesis of systemic sclerosis","volume":"38","author":"Sanges","year":"2017","journal-title":"Rev M\u00e9decine Interne"},{"key":"10.1016\/j.berh.2026.102137_bib83","article-title":"Characteristics and impact of infiltration of B-cells from systemic sclerosis patients in a 3D healthy skin model","volume":"15","author":"Le","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103782","article-title":"Beyond circulating B cells: characteristics and role of tissue-infiltrating B cells in systemic sclerosis","volume":"24","author":"Le Ma\u00eetre","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.berh.2026.102137_bib85","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102137_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100272","article-title":"Autoantibodies in systemic sclerosis: from disease bystanders to pathogenic players","volume":"10","author":"Chepy","year":"2025","journal-title":"J Transl Autoimmun"},{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib88","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2026.102137_bib89","doi-asserted-by":"crossref","unstructured":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples | Rheumatology | Oxford Academic [Internet]. [cited 2025 Dec 30]. Available from: https:\/\/academic.oup.com\/rheumatology\/article\/56\/7\/1227\/3603394?login=false.","DOI":"10.1093\/rheumatology\/kex067"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib92","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2026.102137_bib93","article-title":"CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation","author":"Pecher","year":"2025","journal-title":"EULAR Rheumatol Open"},{"key":"10.1016\/j.berh.2026.102137_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.berh.2026.102137_bib95","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-Cell\u2013Engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102137_bib96","unstructured":"Neonatal Fc receptor: from immunity to therapeutics | J Clin Immunol [Internet]. [cited 2025 Nov 23]. Available from: https:\/\/link.springer.com\/article\/10.1007\/s10875-010-9468-4."},{"issue":"11","key":"10.1016\/j.berh.2026.102137_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103185","article-title":"T cell abnormalities in systemic sclerosis","volume":"21","author":"Jin","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib98","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1038\/s41467-025-60034-7","article-title":"Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis","volume":"16","author":"Shimagami","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2026.102137_bib99","unstructured":"Expression of TL1A, Inflammatory, and fibrotic pathways in patients with diffuse systemic sclerosis. ACR Meeting Abstracts [Internet]. [cited 2025 Nov 24]. Available from: https:\/\/acrabstracts.org\/abstract\/expression-of-tl1a-inflammatory-and-fibrotic-pathways-in-patients-with-diffuse-systemic-sclerosis\/."},{"key":"10.1016\/j.berh.2026.102137_bib100","doi-asserted-by":"crossref","unstructured":"POS0881 EFFICACY AND SAFETY OF SUBCUTANEOUS BRODALUMAB, A fully human anti\u2013il-17ra monoclonal antibody, for systemic sclerosis with moderate-to-severe skin thickening: a multicenter, randomized, placebo-controlled, double-blind phase 3 study | Ann Rheum Dis [Internet]. [cited 2025 Nov 24]. Available from: https:\/\/ard.bmj.com\/content\/81\/Suppl_1\/736.","DOI":"10.1136\/annrheumdis-2022-eular.2519"},{"issue":"6","key":"10.1016\/j.berh.2026.102137_bib101","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","article-title":"Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease","volume":"11","author":"Benschop","year":"2019","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003500","article-title":"Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1\u2013phase 2a study","volume":"10","author":"Barde","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib103","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/23971983241278079","article-title":"Design of CONQUEST, a novel, randomized, placebo-controlled, phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease","volume":"10","author":"Khanna","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2026.102137_bib104","unstructured":"Fibroblast and myofibroblast activation in normal tissue repair and fibrosis | Nat Rev Mol Cell Biol [Internet]. [cited 2025 Dec 11]. Available from: https:\/\/www.nature.com\/articles\/s41580-024-00716-0."},{"key":"10.1016\/j.berh.2026.102137_bib105","unstructured":"TGF-\u03b2 signaling in health, disease and therapeutics | Signal Transduct Targeted Ther [Internet]. [cited 2025 Nov 24]. Available from:: https:\/\/www.nature.com\/articles\/s41392-024-01764-w."},{"key":"10.1016\/j.berh.2026.102137_bib106","unstructured":"\u03b1v integrins: key regulators of tissue fibrosis | Cell Tissue Res [Internet]. [cited 2025 Nov 24]. Available from: https:\/\/link.springer.com\/article\/10.1007\/s00441-016-2407-9."},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib107","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib108","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102137_bib109","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/annrheumdis-2020-eular.1753","article-title":"THU0329 safety, target engagement, and initial efficacy of AVID200, a first-in-class potent and isoform-selective inhibitor of TGF-beta 1 and 3, in patients with diffuse cutaneous systemic sclerosis (DCSSC): a phase 1 dose escalation study","volume":"79","author":"Lafyatis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2026.102137_bib110","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: a phase II study of abituzumab in patients with systemic sclerosis-associated interstitial lung disease","volume":"48","author":"Khanna","year":"2021","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102137_bib111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm.3777","article-title":"Orphan nuclear receptor NR4A1 regulates transforming growth factor-\u03b2 signaling and fibrosis","volume":"21","author":"Palumbo-Zerr","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102137_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204378","article-title":"Vitamin D receptor regulates TGF-\u03b2 signalling in systemic sclerosis","volume":"74","author":"Zerr","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102137_bib113","unstructured":"The JAK\/STAT signaling pathway: from bench to clinic | Signal Transduct Targeted Ther [Internet]. [cited 2025 Nov 25]. Available from: https:\/\/www.nature.com\/articles\/s41392-021-00791-1?fromPaywallRec=false#Sec31."},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/03008207.2018.1500558","article-title":"Oncostatin M and its role in fibrosis","volume":"60","author":"Stawski","year":"2019","journal-title":"Connect Tissue Res"},{"issue":"10","key":"10.1016\/j.berh.2026.102137_bib115","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.berh.2026.102137_bib117","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s10067-025-07433-9","article-title":"BAricitinib in patients with SystemIC sclerosis (BASICS): a prospective, open-label, randomised trial","volume":"44","author":"Chen","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102137_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109723","article-title":"Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis","volume":"116","author":"Bellamri","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"26","key":"10.1016\/j.berh.2026.102137_bib119","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41580-024-00823-y","article-title":"Mechanistic insights into Wnt\u2013\u03b2-catenin pathway activation and signal transduction","volume":"26","author":"Maurice","year":"2025","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"341","key":"10.1016\/j.berh.2026.102137_bib121","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.berh.2026.102137_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2024.105986","article-title":"Porcupine inhibitors LGK-974 and ETC-159 inhibit Wnt\/\u03b2-catenin signaling and result in inhibition of the fibrosis","volume":"104","author":"Ko\u00e7ak","year":"2025","journal-title":"Toxicol Vitro"},{"issue":"5","key":"10.1016\/j.berh.2026.102137_bib124","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.3390\/ijms22052765","article-title":"Butyrate improves skin\/lung fibrosis and intestinal dysbiosis in bleomycin-induced mouse models","volume":"22","author":"Park","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib125","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical Wnt signalling is required for TGF-\u03b2-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.berh.2026.102137_bib126","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2026.102137_bib127","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/art.42477","article-title":"A 24-Week, phase IIa, randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous systemic sclerosis","volume":"75","author":"Khanna","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102137_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1475528","article-title":"Gut microbiome and metabolomics in systemic sclerosis: feature, link and mechanisms","volume":"15","author":"Yao","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.berh.2026.102137_bib129","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004647","article-title":"Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile","volume":"10","author":"Bellando-Randone","year":"2024","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.berh.2026.102137_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283283","article-title":"Whole body insulin sensitivity is increased in systemic sclerosis","volume":"18","author":"Ciaffi","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.berh.2026.102137_bib131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41420-024-02106-z","article-title":"GLUT1 inhibitor BAY-876 induces apoptosis and enhances anti-cancer effects of bitter receptor agonists in head and neck squamous carcinoma cells","volume":"10","author":"Miller","year":"2024","journal-title":"Cell Death Discov"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:26:21Z","timestamp":1785878781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1521694226000227"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102137","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and molecular mechanisms of systemic sclerosis: Translation to targeted therapies and clinical practice","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102137"}}